- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04994483
Simufilam 100 mg for Mild-to-Moderate Alzheimer's Disease (RETHINK-ALZ)
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 mg Tablets in Subjects With Mild-to-Moderate Alzheimer's Disease
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The primary objective of this study is to investigate the safety and efficacy of simufilam (PTI-125) in enhancing cognition and slowing cognitive and functional decline following 52-week, repeat-dose oral administration in participants with mild-to-moderate AD. Secondary objectives include the assessment of simufilam's effect on neuropsychiatric symptoms and caregiver burden. A third objective is to investigate the effect of simufilam treatment on plasma biomarkers. A limited number of research sites will be invited to participate in the pharmacokinetic (PK) and plasma biomarker sub-study. Collection of PK samples will enable an exposure-response analysis. Approximately 100 subjects will participate (50 per group). Plasma samples will be collected during the Screening Visit and again at Weeks 28 and 52. Change from Baseline for plasma biomarkers represent additional secondary endpoints.
Safety will be evaluated by adverse event monitoring, vital signs, clinical labs, and the Columbia Suicide Severity Rating Scale at every visit. Subjects will undergo magnetic resonance imaging (MRI) during screening to ensure entry criteria are met (unless recent MRI confirms entry criteria). Resting electrocardiograms will be conducted at Baseline (Study Day 1) and Weeks 4, 28, and 52. A complete physical and neurological examination will be performed at screening, and brief examinations will be performed at all other visits. Weight will be measured during the Screening Period, at Baseline (Study Day 1), and at all other visits.
An independent Data Safety Monitoring Board (DSMB) will meet periodically to review subject safety assessments and determine if dosing may continue. A charter will be developed with specific guidance for the DSMB.
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Study Director
- Phone Number: 737-910-1045
- Email: ClinicalTrials.gov@cassavasciences.com
Study Locations
-
-
New South Wales
-
Macquarie Park, New South Wales, Australia, 2113
- KaRa MINDS
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- The University of Queensland
-
Southport, Queensland, Australia, 4215
- Impact Health Pty Ltd.
-
-
Victoria
-
Box Hill, Victoria, Australia, 3128
- Eastern Health
-
Glen Iris, Victoria, Australia, 3146
- Delmont Private Hospital
-
Heidelberg, Victoria, Australia, 3084
- Austin Health
-
Melbourne, Victoria, Australia, 3004
- The Alfred Hospital
-
Parkville, Victoria, Australia, 3050
- Royal Melbourne Hospital
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 8009
- Australian Alzheimer's Research Foundation
-
-
-
-
-
Québec, Canada, G3K 2P8
- ALPHA Recherche Clinique
-
-
Ontario
-
London, Ontario, Canada, N6A 5R9
- LMC Clinical Research - London
-
Sarnia, Ontario, Canada, N7t 4X3
- Bluewater Clinical Research Group Inc
-
-
Quebec
-
Sherbrooke, Quebec, Canada, J1J 2G2
- Q & T Research
-
Sherbrooke, Quebec, Canada, J1L0H8
- Diex Research Sherbrooke Inc.
-
-
-
-
Arizona
-
Chandler, Arizona, United States, 85286
- MDFirst Research
-
Gilbert, Arizona, United States, 85297
- CCT Research - Gilbert Neurology Partners
-
Phoenix, Arizona, United States, 85004
- Xenoscience, Inc.
-
-
California
-
Anaheim, California, United States, 92805
- Advanced Research Center, Inc
-
Colton, California, United States, 92324
- Axiom Research, LLC
-
Costa Mesa, California, United States, 92626
- ATP Clinical Research, Inc.
-
Imperial, California, United States, 92251
- Sun Valley Research Center, Inc.
-
Laguna Hills, California, United States, 92653
- Senior Clinical Trials
-
Riverside, California, United States, 92503
- Artemis Institute for Clinical Research
-
Santa Ana, California, United States, 92705
- Syrentis Clinical Research
-
-
Colorado
-
Basalt, Colorado, United States, 81621
- Mountain Neurological Research Center
-
Denver, Colorado, United States, 80210
- Colorado Neurological Research Center, PC
-
-
Connecticut
-
Cromwell, Connecticut, United States, 06416
- CT Clinical Research
-
-
Florida
-
Apopka, Florida, United States, 32703
- Topaz Clinical Research
-
Boca Raton, Florida, United States, 33428
- Neurology Offices of South Florida
-
Boynton Beach, Florida, United States, 33437
- Boynton Beach Medical Research Institute (GMI)
-
Clermont, Florida, United States, 34711
- K2 Medical Research - Clermont
-
Daytona Beach, Florida, United States, 32117
- Arrow Clinical Trials
-
Fort Myers, Florida, United States, 33912
- Neuropsychiatric Research Center of Southwest Florida
-
Hallandale Beach, Florida, United States, 33009
- Velocity Clinical Research, Hallandale Beach
-
Hialeah, Florida, United States, 33016
- Galiz Research
-
Hollywood, Florida, United States, 33024
- Infinity Clinical Research - Sunrise
-
Jacksonville, Florida, United States, 32256
- CNS Healthcare - Jacksonville
-
Lady Lake, Florida, United States, 32162
- Charter Research
-
Lauderhill, Florida, United States, 33319
- Segal Trials - West Broward Outpatient Site
-
Maitland, Florida, United States, 32751
- ClinCloud
-
Merritt Island, Florida, United States, 32952
- Merritt Island Medical Research, LLC
-
Miami, Florida, United States, 33165
- New Horizon Research Center
-
Miami, Florida, United States, 33125
- Central Miami Medical Institute (GMI)
-
Miami, Florida, United States, 33186
- Luminous Clinical Research
-
Miami Beach, Florida, United States, 33140
- Quantam Clinical Trials
-
Miami Springs, Florida, United States, 33166
- South Florida Research Phase I-IV INC
-
New Port Richey, Florida, United States, 34652
- Suncoast Clinical Research, Inc.
-
Ocala, Florida, United States, 34470
- Renstar Medical Research
-
Orlando, Florida, United States, 32807
- Combined Research Orlando Phase I-IV
-
Port Orange, Florida, United States, 32127
- Progressive Medical Research
-
Tampa, Florida, United States, 33613
- Stedman Clinical Trials
-
Tampa, Florida, United States, 33603
- Clinical Research of Brandon, LLC (Tampa)
-
West Palm Beach, Florida, United States, 33407
- Premier Research Institute at Palm Beach Neurology
-
Winter Park, Florida, United States, 32792
- Charter Research
-
-
Idaho
-
Meridian, Idaho, United States, 83642
- Velocity Clinical Research, Boise
-
-
Illinois
-
Winfield, Illinois, United States, 60190
- Northwestern Medicine Central DuPage Hospital
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Ascension Via Christi Research
-
-
Louisiana
-
Alexandria, Louisiana, United States, 71301
- Neuro Medical Clinic of Central Louisiana, LLC
-
-
Massachusetts
-
North Dartmouth, Massachusetts, United States, 02747
- Boston Neuro Research Center
-
-
Missouri
-
Chesterfield, Missouri, United States, 63005
- Clinical Research Professionals
-
-
Nebraska
-
Papillion, Nebraska, United States, 68046
- CCT Research - Papillion Research Center
-
-
New Jersey
-
West Long Branch, New Jersey, United States, 07764
- Advanced Clinical Institute, Inc
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87109
- Albuquerque Neuroscience, Inc
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurologic Institute
-
New Hyde Park, New York, United States, 11040-1433
- Parker Jewish Institute for Health Care & Rehabilitation
-
New Windsor, New York, United States, 12553
- Mid Hudson Medical Research
-
New York, New York, United States, 10003
- NY Neurology Associates
-
Rochester, New York, United States, 14620
- University of Rochester Medical Center - Alzheimer's Disease Care, Research and Education Program
-
Woodmere, New York, United States, 11598
- Five Town Neuroscience Research
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27410
- Triad Clinical Trials, LLC
-
Matthew, North Carolina, United States, 28105
- Alzheimer's Memory Center
-
-
Ohio
-
Beachwood, Ohio, United States, 44122
- Insight Clinical Trials LLC
-
Canton, Ohio, United States, 44718
- NeuroScience Research Center, LLC
-
Centerville, Ohio, United States, 45459
- Dayton Center for Neurological Disorders
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Research Network, LLC
-
-
Pennsylvania
-
Malvern, Pennsylvania, United States, 19355
- Brian Abaluck, LLC
-
Moosic, Pennsylvania, United States, 18507
- Global Medical Institutes/Scranton Medical Institute - Moosic Division
-
-
Rhode Island
-
East Providence, Rhode Island, United States, 02914
- Rhode Island Mood & Memory Research Institute
-
-
South Carolina
-
Summerville, South Carolina, United States, 29485
- Palmetto Clinical Research
-
-
Texas
-
Austin, Texas, United States, 78731
- FutureSearch Trials of Neurology
-
Austin, Texas, United States, 78757
- Senior Adults Specialty Research, Inc
-
Dallas, Texas, United States, 75206
- Texas Neurology, PA
-
Dallas, Texas, United States, 75231
- Baylor Scott & White Research Institute
-
Katy, Texas, United States, 77450
- Mt. Olympus Medical Research, LLC
-
Wichita Falls, Texas, United States, 76309
- Grayline Research Center
-
-
Vermont
-
Rutland, Vermont, United States, 05701
- Green Mountain Research Institute, Inc.
-
-
Virginia
-
Fairfax, Virginia, United States, 22031
- Re:Cognition Health
-
-
Washington
-
Seattle, Washington, United States, 98104
- Memory and Brain Wellness Center at Harborview
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Meets National Institute on Aging and Alzheimer's Association Research Framework criteria for individuals in clinical Stage 4 or 5 of the Alzheimer's continuum.
- Evidence for AD pathophysiology, confirmed either prior to or during screening.
- MMSE score ≥ 16 and ≤ 27 at screening.
- Clinical Dementia Rating - Global Score must be 0.5, 1 or 2.
- If receiving background AD medications, the dosing regimen must be stable for at least 12 weeks prior to randomization. Chronic medications for conditions other than AD (such as depression) must be prescribed at a stable dose for at least 4 weeks prior to screening.
- The subject has not been a cigarette smoker or chewed tobacco for at least 3 years.
- Availability of a study partner.
- Individuals who have participated in a clinical study with an investigational drug targeting the underlying AD process may be permitted to participate in this study.
- Completed a COVID-19 vaccine primary series ("fully vaccinated") at least 2 weeks prior to randomization or had an unambiguous COVID-19 infection diagnosed more than 3 months before the start of the Screening Period.
Key Exclusion Criteria:
- A neurologic condition other than AD that significantly contributes to the subject's dementia.
- Any current primary psychiatric diagnosis other than AD if it is likely to confound cognitive assessment or ability to comply with study procedures.
- Geriatric Depression Scale (15-item) score > 8. (Note - a subject with a score > 8 may continue in screening if, in the judgment of the Investigator, the elevated score is not attributed to a major depressive episode).
- Suicidal ideation during the past 3 months or suicidal behavior during the past 12 months.
- Alcohol or substance use disorder within 2 years of screening.
- MRI presence of cerebral vascular or other significant pathology.
- History of transient ischemic attack or stroke within 12 months of screening
- Seizure within 12 months of screening.
- Severe head trauma or head trauma considered likely to be contributing to the subject's cognitive impairment.
- Sleep apnea that is considered likely to be contributing to the subject's cognitive impairment.
- Insufficiently controlled diabetes mellitus or hypertension.
- Body mass index < 18.5 or > 37.5.
- History or diagnosis of clinically significant cardiac disease
- Currently or previously prescribed/administered aducanumab, lecanemab, or any anti-amyloid monoclonal antibody, more than 2 doses.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Matching placebo, supplied by Cassava as coated tablets, and taken twice daily (b.i.d.) for 52 weeks
|
Matching placebo given b.i.d. for 52 weeks.
|
Experimental: Simufilam 100 mg
Simufilam 100 mg, supplied by Cassava as coated tablets, and taken b.i.d. for 52 weeks
|
Simufilam is a novel drug candidate designed to treat and slow the progression of AD.
Simufilam binds with femtomolar affinity to an altered conformation of filamin A that is present in the brain of patients with AD and critical to the toxicity of Aβ42.
In this study, simufilam will be given b.i.d. for 52 weeks at a dose of 100 mg.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the 12-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog12)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the ADAS-Cog12, a psychometrician-administered battery comprised of several cognitive domains including memory, comprehension, praxis, orientation, and spontaneous speech.
Scores range from 0 (best) to 80 (worst).
|
Baseline (Study Day 1) to Week 52
|
Change from baseline in the Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the ADCS-ADL, a 23-item study partner questionnaire that covers both basic activities of daily living (ADL) and more complex ADL or instrumental ADL.
Scores range from 0 to 78, with a lower score indicating greater severity of functional loss.
|
Baseline (Study Day 1) to Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline in the integrated Alzheimer's Disease Rating Scale (iADRS)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the iADRS, where scores range from 0 to 146 with lower scores indicating worse performance.
|
Baseline (Study Day 1) to Week 52
|
Change from baseline in the Neuropsychiatric Inventory (NPI)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the NPI, a 12-item study partner interview, which records the frequency and severity of common neuropsychiatric symptoms in dementia, as well as the level of study partner distress due to each of the neuropsychiatric problems.
Scores range from 0 to 144, with higher scores indicating more frequent and severe symptoms, and greater levels of partner distress.
|
Baseline (Study Day 1) to Week 52
|
Change from baseline in the Clinical Dementia Rating Sum of Boxes (CDR-SB)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the CDR-SB, which characterizes 6 domains of cognitive and functional performance applicable to AD and related dementias: memory, orientation, judgment and problem solving, community affairs, home and hobbies, and personal care.
Higher scores indicate more severe impairment.
|
Baseline (Study Day 1) to Week 52
|
Change from baseline in the Zarit Burden Interview (ZBI)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the ZBI, a 22-item study partner questionnaire designed to assess the stress or burden experienced by caregivers of people with dementia, with a higher score indicating greater stress or burden.
|
Baseline (Study Day 1) to Week 52
|
Changes from baseline in the plasma SavaDx biomarker
Time Frame: Baseline (Study Day 1) to Week 52
|
Change from baseline in SavaDx, a novel plasma biomarker
|
Baseline (Study Day 1) to Week 52
|
Change from baseline in the Mini-Mental State Exam (MMSE)
Time Frame: Baseline (Study Day 1) to Week 52
|
The change from baseline to Week 52 in the MMSE, a set of standardized questions covering several target areas: orientation, registration, attention and calculation, short-term verbal recall, naming, repetition, 3-step command, reading, writing, and visuospatial cognitive assessment.
Lower scores indicate more severe impairment.
|
Baseline (Study Day 1) to Week 52
|
Changes from baseline in plasma phospho-tau181 (P-tau181) and/or phospho-tau217 (P-tau217), and neurofilament light chain.
Time Frame: Baseline (Study Day 1) to Week 52
|
Change from baseline in plasma biomarkers of AD pathology, neurodegeneration, and neuroinflammation.
|
Baseline (Study Day 1) to Week 52
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jim Kupiec, MD, Cassava Sciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PTI-125-07
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States